Eli Lilly has made a significant move by agreeing to acquire Centessa Pharmaceuticals for approximately $7.8 billion. This strategic acquisition aims to bolster Lilly’s neuroscience pipeline, particularly in the realm of sleep disorders.
The agreement entails a purchase price of up to $47 per share, elevating the total deal value to around $7.8 billion. This acquisition underscores Lilly’s commitment to expanding its capabilities in treating complex neurological conditions.
Expanding Treatment Options
Centessa Pharmaceuticals is a clinical-stage company renowned for developing orexin receptor 2 (OX2R) agonists. These compounds aim to address excessive daytime sleepiness and a variety of disorders related to impaired wakefulness. Their leading candidate, cleminorexton, has shown promise in Phase IIa trials, potentially positioning it as a best-in-class treatment for conditions like narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia.
In addition to cleminorexton, Centessa brings a diverse portfolio of clinical and preclinical assets that could be beneficial for various neurological, neurodegenerative, and neuropsychiatric conditions. This breadth of offerings aligns well with Lilly’s objectives to enhance its therapeutic range.
The Significance of Orexin Biology
The orexin system serves as a crucial regulator of the sleep-wake cycle in the brain. A deficiency in orexin signaling is a primary factor in narcolepsy type 1, while disrupted orexin activity can lead to other wakefulness disorders. OX2R agonists present a unique approach to restoring wakefulness, distinguishing themselves from traditional stimulant-based therapies.
Carole Ho, Lilly’s executive vice president and president of Lilly Neuroscience, emphasized the potential of orexin receptor biology. She stated that it represents a compelling mechanistic opportunity in neuroscience, enabling direct interventions in sleep-wake dynamics. Joining Centessa’s expertise will allow Lilly to pursue this potential effectively.
Financial Terms of the Deal
Under the terms of the acquisition, Lilly will pay $38.00 per share in cash upon closing. This price represents an aggregate equity value of approximately $6.3 billion, reflecting a 40.5% premium over Centessa’s 30-day volume-weighted average trading price. Additionally, there is a non-transferable contingent value right (CVR) valued at up to $9.00 per share, contingent on the achievement of three regulatory milestones.
These milestones include FDA approvals for cleminorexton or ORX142 for narcolepsy type 2, FDA approval for idiopathic hypersomnia, and a first FDA approval for any indication before January 1, 2030. The CVR could contribute an extra potential equity value of around $1.5 billion, showcasing the high stakes involved in this acquisition.
A Growing Trend in Deal-Making
This acquisition is part of a broader trend of aggressive deal-making by Eli Lilly. The company has been strategically investing in areas such as obesity, neuroscience, and artificial intelligence drug discovery. This diversification strategy comes as Lilly seeks to extend its reach beyond its successful GLP-1 franchise.
Future Prospects and Innovations
Mario Alberto Accardi, CEO of Centessa, articulated the company’s commitment to exploring orexin pharmacology through validated non-clinical studies. The goal is to unlock the full potential of their multi-asset OX2R agonist pipeline, which could provide new therapeutic options for managing mood symptoms, excessive daytime sleepiness, cognitive deficits, and fatigue across various neurological conditions.
The partnership with Centessa also opens avenues to expand the OX2R pipeline beyond rare hypersomnias and into more prevalent conditions with significant unmet clinical needs. This focus on innovation positions Lilly to make impactful advancements in neuroscience.
Conclusion
Eli Lilly’s acquisition of Centessa Pharmaceuticals marks a pivotal step in the company’s quest to enhance treatments for sleep-wake disorders. With a robust portfolio of innovative assets and a commitment to advancing orexin biology, this collaboration holds the potential to reshape the landscape of neuroscience. As Lilly continues to navigate the complexities of modern pharmaceuticals, strategic acquisitions like this will be crucial for driving future growth and innovation.
- Eli Lilly acquires Centessa for $7.8 billion to enhance its neuroscience portfolio.
- The acquisition focuses on orexin receptor agonists aimed at treating sleep disorders.
- Cleminorexton, Centessa’s lead candidate, shows promise in clinical trials.
- The deal includes potential contingent value rights tied to regulatory milestones.
- Lilly seeks to diversify its offerings beyond its blockbuster GLP-1 drugs.
Read more → www.pharmexec.com